ideasIdea
A trial of GLP-1 weight-loss drugs with cancer as the primary outcome
Obesity raises the risk of 13 cancers. Weight-loss drugs are now widely used; a large trial should test whether they actually prevent cancer, not just diabetes and heart disease.
Observational data suggest GLP-1 receptor agonists reduce obesity-related cancer incidence, but confounding is severe. Propose an RCT, or prospective cancer adjudication embedded in ongoing cardiovascular outcome trials, with incident obesity-related cancer as the primary endpoint in adults aged 50-70 with BMI of 30 or more.
Hypothesis
GLP-1 receptor agonist therapy reduces incidence of obesity-related cancers by at least 20% over seven years.
Rationale
Bariatric surgery reduces cancer incidence in cohort studies; pharmacological weight loss may reproduce this through insulin/IGF and inflammatory pathways.
What would test it
Run a 20,000-person RCT or a pooled analysis of cardiovascular outcome trials with prospective cancer adjudication.
Maturity
early clinical
Who has to act
industry
Cost to try
Large (over $50M)
Years to first evidence
8
Bottlenecks it attacks
- Prevention we already have is not deployed · Around four in ten cancers are preventable with tools we already own: vaccines, tobacco control, weight, alcohol, sun and infection control.